Canadian treatments for COVID-19 (CATCO) trials receive approval from Health Canada to change protocol to include LSALT peptide (Metablok)
Canadian treatments for COVID-19 (CATCO) trials receive approval from Health Canada to change protocol to include LSALT peptide (Metablok)

Canadian treatments for COVID-19 (CATCO) trials receive approval from Health Canada to change protocol to include LSALT peptide (Metablok)

Arch Biopartners

LSALT Peptide (LSALT) is a new drug candidate that targets acute organ inflammation in the lungs, liver and kidneys, which is common in several indications, including moderate to severe cases of COVID-19, regardless of variant type

TORONTO, February 14, 2022 (GLOBE NEWSWIRE) – Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or “The Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a company in the clinical phase developing new drug candidates for the treatment of organ damage caused by inflammation, announced today that Health Canada has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide (LSALT and “Metablok”) in a new dosing arm of the trial.

Health Canada has issued one No letter of objection for the clinical trial application – Modification of the CATCO team as part of its approval process. Dosage of LSALT peptide is expected to begin after final local approval and preparation at the clinical site.

About CATCO

CATCO is a multicenter, adaptive, randomized, open-label, controlled trial conducted in up to 55 hospitals across Canada to find new treatments for patients suffering from complications caused by COVID-19. CATCO is supported by the Canadian Network of COVID-19 Clinical Trials Networks, which is funded by the Canadian Institutes of Health Research.

The Sunnybrook Research Institute (SRI) sponsors the CATCO trial and administers the trial across all locations in Canada. SRI has entered into a collaboration agreement with Arch Biopartners to use LSALT in a new part of the CATCO trial. The company’s primary responsibility during the trial is the delivery of LSALT drug vials to support the dosing of up to approx. 350 patients.

About COVID-19

COVID-19 is the disease caused by the new coronavirus SARS-CoV-2, which appeared in China in late 2019. Serious complications of COVID-19 are largely due to the excessive host immune response to the virus, which results in progressive pneumonia and acute respiratory distress syndrome, often requiring mechanical ventilation and critical care.1. Patients with severe COVID-19 also experience dysfunction of several organs, including acute kidney damage, liver dysfunction, heart failure, and blood abnormalities.

Although vaccination has been shown to be effective in limiting the severity of COVID-19, vaccine delays, limited vaccine access globally as well as the emergence of new SARS-CoV-2 variants have perpetuated the global pandemic. Survival rates and health system capacity can both be improved with new treatments that prevent the serious manifestations of COVID-19, such as exacerbation of pneumonia (ARDS) and AKI experienced by patients infected with SARS-CoV-2. Targeting inflammation to reduce the severity of COVID-19 is a therapeutic strategy that should not be affected by the emergence of SARS-CoV-2 variants.

1Wong, LY., Perlman, S. Immune regulation and immunopathology induced by SARS-CoV-2 and related coronavirus – are we our own worst enemy? Nat Rev Immunol (2021). https://doi.org/10.1038/s41577-021-00656-2

About Arch Biopartners

Arch Biopartners Inc. is a company in the clinical phase that focuses on the development of innovative technologies that have the potential to have a significant medical or commercial effect. Arch is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway, relevant to several medical indications.

For more information on Arch Biopartners, its technologies and other public documents Arch has archived on SEDAR, please visit www.archbiopartners.com

The company has 62,120,292 outstanding ordinary shares.

Other Business Articles – Correction February 8, 2022 Press Release

An error was made in the Arch press release of 8. February 2022 with respect to the interest period used to calculate the interest debt for equity settlement. The press release was to read: “The company has arranged a share for the debt transaction to settle a total amount of $ 424,767.07 in interest accrued up to September 31st, 2021… ”and not 31 December 2021 as originally reported. This interest amount is the same as reported in the company’s audited financial statements for the financial year ending 31 September 2021, submitted to SEDAR on 28 January 2022.

For more information, please contact:

Richard Muruve
CEO
Arch Biopartners Inc
1 647 428 7031

Please send a message or subscribe to email alerts on the company website using the link here www.archbiopartners.com/contact-us

Forward-looking statements

This press release contains forward-looking statements and forward-looking information, or overall forward-looking statements, in accordance with applicable securities laws, based on Arch Biopartners’ management beliefs and assumptions and on information currently available to Arch Biopartners. ‘management. All statements, except statements about historical facts, in this news release are considered forward-looking statements involving various risks and uncertainties, including, without limitation, statements about the company’s future plans and objectives. No assurance can be given that such statements will prove to be accurate. Actual results and future events may differ materially from those expected in such statements. Forward-looking statements can be identified by terms such as “can”, “will”, “should”, “could”, “would”, “prospects”, “believe”, “plan”, “anticipate”, “expect” and “estimate” “or the negative of these terms or variations thereof. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the potential efficacy and safety of LSALT peptide (LSALT) in patients who have inflammation of the lungs and other organs such as the liver and kidneys; the ongoing clinical development of LSALT in future human trials and other indications outside COVID-19 patients.

Forward-looking statements are based on a number of assumptions and include, but are not limited to, the following: results observed in preclinical in-vivo studies; previous human trials, including a Phase I and a Phase II study in which LSALT was dosed to human patients; previous results of the network of hospitals involving other trials and dosing of other treatments for COVID-19 patients; the ability of participating hospitals to enroll a sufficient number of patients to complete the study of LSALT in the planned number of COVID-19 patients; and the worsening or declining COVID-19 pandemic will not adversely affect the development of LSALT and other DPEP-1-targeted drugs in Arch Biopartners’ portfolio of new drugs under development.

Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which may cause our actual results to differ materially from those disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include the risk that results (whether safety or efficacy, or both) obtained by administering LSALT to humans will not be similar to those obtained in preclinical studies or in the previously completed phase. I and Phase II trials; the risk that the hospitals participating in the CATCO trial will not be able to enroll enough patients to complete the study of LSALT as a treatment for organ inflammation in COVID-19 patients; or that serious adverse reactions due to the administration of LSALT are detected, leading to the suspension or cancellation of any development work with LSALT; and the risk of new organ inflammation treatments being detected or introduced by competitors that may prove safer and / or more effective than LSALT.

We refer potential investors to the “Risk Factors” section of our annual management and discussion and analysis dated January 28, 2022 available on SEDAR at www.sedar.com and on our website at www.archbiopartners.com for additional risks relating to Arch Biopartners’ business and business in general. The reader is warned to consider these and other risks and uncertainties carefully and not to rely unnecessarily on forward-looking statements. Forward-looking statements reflect current expectations for future events and apply only from the date of this press release and represent management’s expectations as of this date.

Arch Biopartners’ management undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

The scientific and medical content of this publication has been approved by the company’s Chief Science Officer

The company makes no express or implied claims that its product has the ability to eliminate, cure or contain Covid-19 (or SARS-2 Coronavirus) at present.

Neither TSX Venture Exchange nor its regulatory service provider (as this term is defined in TSX Venture Exchange’s policies) assumes responsibility for the adequacy or accuracy of this release.

Leave a Reply

Your email address will not be published.